RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation (Q24292999)

1

0 references

John Chan

3

0 references

Marco Wallroth

4

0 references

Laura Tandeske

5

0 references

Huili Zhai

6

0 references

John Tellew

7

0 references

Stephen Hardy

8

0 references

Mohammad Hekmat-Nejad

9

0 references

Darrin D Stuart

10

0 references

Frank McCormick

11

0 references

Tobi E Nagel

Physiological concentrations of purines and pyrimidines

12

0 references

language of work or name

English

0 references

publication date

13 May 2013

0 references

published in

Cancer Cell

0 references

volume

23

0 references

page(s)

594-602

0 references

issue

5

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Protein kinase C alpha activates RAF-1 by direct phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

A dimerization-dependent mechanism drives RAF catalytic activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Positive and negative regulation of Raf kinase activity and function by phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.033

7 January 2021

10.1016/J.CCR.2013.03.033

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

3898237

3898237

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference